Overview:

Summary

GlobalData, the industry analysis specialist, has released its new report, “Diabetic Nephropathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Diabetic Nephropathy Therapeutics market. The report identifies the key trends shaping and driving the global Diabetic Nephropathy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Diabetic Nephropathy Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Diabetic Nephropathy Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Diabetic Nephropathy Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Diabetic Nephropathy Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Diabetic Nephropathy Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Diabetic Nephropathy Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Diabetic Nephropathy Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Diabetic Nephropathy Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Diabetic Nephropathy Therapeutics market landscape? – Identify, understand and capitalize."

Companies Mentioned

Reata Pharmaceuticals, Inc.
Eli Lilly and Company
Abbott Laboratories
Pfizer
Sanofi-Aventis

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Diabetic Nephropathy Therapeutics: Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 8
2.3 Etiology 8
2.4 Pathophysiology 9
2.5 Signs and Symptoms 9
2.6 Commonly Used Diagnosis Tests 10
2.7 Treatment and Management Options for Diabetic Nephropathy 11
2.8 GlobalData Pipeline Report Guidance 12
3 Diabetic NephropathyTherapeutics: Market Characterization 13
3.1 Diabetic Nephropathy Therapeutics Market Size (2005–2010) – Global 13
3.2 Diabetic Nephropathy Therapeutics Market Forecast (2010–2017) – Global 14
3.3 Diabetic Nephropathy Therapeutics Market Size (2005–2010) – The US 15
3.4 Diabetic Nephropathy Therapeutics Market Forecast (2010–2017) – The US 16
3.5 Diabetic Nephropathy Therapeutics Market Size (2005–2010) – France 17
3.6 Diabetic Nephropathy Therapeutics Market Forecast (2010–2017) – France 18
3.7 Diabetic Nephropathy Therapeutics Market Size (2005-2010) – Germany 19
3.8 Diabetic Nephropathy Therapeutics Market Forecast (2010–2017) – Germany 20
3.9 Diabetic Nephropathy Therapeutics Market Size (2005–2010) – Italy 21
3.10 Diabetic Nephropathy Therapeutics Market Forecast (2010–2017) – Italy 22
3.11 Diabetic Nephropathy Therapeutics Market Size (2005–2010) – Spain 23
3.12 Diabetic Nephropathy Therapeutics Market Forecast (2010–2017) – Spain 24
3.13 Diabetic Nephropathy Therapeutics Market Size (2005–2010) – The UK 25
3.14 Diabetic Nephropathy Therapeutics Market Forecast (2010–2017) – The UK 26
3.15 Diabetic Nephropathy Therapeutics Market Size (2005–2010) – Japan 27
3.16 Diabetic Nephropathy Therapeutics Market Forecast (2010–2017) – Japan 28
3.17 Drivers and Barriers for the Diabetic Nephropathy Therapeutics Market 29
3.17.1 Drivers for the Diabetic Nephropathy Therapeutics Market 29
3.17.2 Barriers for the Diabetic Nephropathy Therapeutics Market 29
3.18 Opportunity and Unmet Need Analysis 30
3.19 Key Takeaway 31
4 Diabetic Nephropathy Therapeutics: Competitive Assessment 32
4.1 Overview 32
4.2 Strategic Competitor Assessment 32
4.3 Product Profiles for the Major Marketed Products in the Diabetic Nephropathy Therapeutics Market 33
4.3.1 Avapro (Irbesartan) 33
4.3.2 Cozaar (Losartan) 34
4.3.3 Capoten (Captopril) 35
4.4 Key Takeaway 35
5 Diabetic Nephropathy Therapeutics: Pipeline Assessment 36
5.1 Overview 36
5.2 Strategic Pipeline Assessment 36
5.3 Diabetic Nephropathy Therapeutics Pipeline – Pipeline by Phases of Development 36
5.3.1 Diabetic Nephropathy Therapeutics – Phase II Pipeline 37
5.3.2 Diabetic Nephropathy Therapeutics – Phase I Pipeline 37
5.3.3 Diabetic Nephropathy Market – Pre-Clinical Pipeline 37
5.3.4 Technology Trends Analytic Framework 38
5.4 Diabetic Nephropathy Therapeutics Market – Clinical Pipeline by Mechanism of Action 40
5.5 Diabetic Nephropathy Therapeutics – Promising Drugs in Clinical Development 41
5.6 Molecule Profile for Promising Drugs in Clinical Development 41
5.6.1 Bardoxolone Methyl 41
5.6.2 Bindarit 42
5.6.3 Pyridorin 43
5.7 Key Takeaway 44
6 Diabetic Nephropathy Therapeutics: Clinical Trials Mapping 45
6.1 Clinical Trials by Region and Country (US, EU5 and Japan) 45
6.2 Clinical Trials by Phase 46
6.3 Clinical Trials by Trial Status 47
6.4 Prominent Sponsors 48
6.5 Top Companies Participating in Diabetic Nephropathy Therapeutics Clinical Trials 50
7 Strategic Assessment 51
7.1 Key Events Impacting the Future Market 51
7.2 Diabetic Nephropathy Therapeutics: Implications for Future Market Competition 52
8 Diabetic Nephropathy Therapeutics: Future Players 53
8.1 Introduction 53
8.2 Company Profiles 53
8.2.1 Reata Pharmaceuticals, Inc. 53
8.2.2 Eli Lilly and Company 55
8.2.3 Abbott Laboratories 57
8.2.4 Pfizer 61
8.2.5 Sanofi-Aventis 65
8.2.6 Other Companies in the Diabetic Nephropathy Therapeutics Market 67
9 Diabetic Nephropathy Therapeutics: Licensing and Partnership Deals 68
10 Diabetic Nephropathy Therapeutics: Appendix 71
10.1 Abbreviations 71
10.2 Market Definitions 72
10.3 Methodology 72
10.3.1 Coverage 72
10.3.2 Secondary Research 72
10.3.3 Forecasting 73
10.3.4 Epidemiology-based Forecasting 73
10.3.5 Primary Research 76
10.3.6 Expert Panel Validation 76
10.4 Contact Us 76
10.5 Disclaimer 76
10.6 Bibliography 77"

1.1 List of Tables
Table 1: Stages of Diabetic Nephropathy 7
Table 2: Diagnosis Criteria for CKD Stages 10
Table 3: FDA Approved Drugs For the Treatment of Diabetic Nephropathy 11
Table 4: Diabetic Nephropathy Therapeutics Market, Global, Revenue ($m), 2005–2010 13
Table 5: Diabetic Nephropathy Therapeutics Market, Global, Forecast ($m), 2010–2017 14
Table 6: Diabetic Nephropathy Therapeutics Market, The US, Revenue ($m), 2005–2010 15
Table 7: Diabetic Nephropathy Therapeutics Market, The US, Forecasts ($m), 2010–2017 16
Table 8: Diabetic Nephropathy Therapeutics Market, France, Revenue ($m), 2005–2010 17
Table 9: Diabetic Nephropathy Therapeutics Market, France, Forecasts ($m), 2010–2017 18
Table 10: Diabetic Nephropathy Therapeutics Market, Germany, Revenue ($m), 2005–2010 19
Table 11: Diabetic Nephropathy Therapeutics Market, Germany, Forecasts ($m), 2010–2017 20
Table 12: Diabetic Nephropathy Therapeutics Market, Italy, Revenue ($m), 2005–2010 21
Table 13: Diabetic Nephropathy Therapeutics Market, Italy, Forecasts ($m), 2010–2017 22
Table 14: Diabetic Nephropathy Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Table 15: Diabetic Nephropathy Therapeutics Market, Spain, Forecasts ($m), 2010–2017 24
Table 16: Diabetic Nephropathy Therapeutics Market, The UK, Revenue ($m), 2005–2010 25
Table 17: Diabetic Nephropathy Therapeutics Market, The UK, Forecasts ($m), 2010–2017 26
Table 18: Diabetic Nephropathy Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Table 19: Diabetic Nephropathy Therapeutics Market, Japan, Forecasts ($m), 2010–2017 28
Table 20: Diabetic Nephropathy Therapeutics – Phase II Pipeline, 2010 37
Table 21: Diabetic Nephropathy Therapeutics – Phase I Pipeline, 2010 37
Table 22: Diabetic Nephropathy  Therapeutics –Pre-Clinical Pipeline, 2010 37
Table 23: Diabetic Nephropathy Therapeutics – Most Promising Drugs In Clinical Development, 2010 41
Table 24: Diabetic Nephropathy Therapeutics – Clinical Trials by Country, 2010 45
Table 25: Diabetic Nephropathy Therapeutics - Clinical Trials by Phase, 2010 46
Table 26: Diabetic Nephropathy Therapeutics - Clinical Trials by Status, 2010 47
Table 27: Diabetic Nephropathy Therapeutics - Prominent Sponsors, 2010 49
Table 28:  Diabetic Nephropathy Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2010 50
Table 29: Reata Pharmaceuticals, Inc – Diabetic Nephropathy, Pipeline, 2010 54
Table 30: Reata Pharmaceuticals, Inc – Deals 54
Table 31: Eli Lilly and Company – Metabolic Disorder, Pipeline, 2010 55
Table 32: Eli- Lilly and Company-Deals 56
Table 33: Abbott Laboratories - Diabetic Nephropathy, Pipeline, 2010 57
Table 34: Abbott Laboratories-Deals 58
Table 35: Pfizer – Metabolic Disorder, Pipeline, 2010 62
Table 36: Pfizer-Deals 63
Table 37: Metabolic Disorder, Pipeline, 2010 65
Table 38: Sanofi-Aventis, Deals, 2009-2011 66
Table 39: Diabetic Nephropathy Therapeutics Market – Future Players 67
Table 40: Diabetic Nephropathy, Global, Deals, 2010 68"

1.2 List of Figures
Figure 1: Diabetic Nephropathy 8
Figure 2: Progression of Diabetic Nephropathy 9
Figure 3: Diabetic Nephropathy Therapeutics Market, Global, Revenue ($m), 2005–2010 13
Figure 4: Diabetic Nephropathy Therapeutics Market, Global, Forecast ($m), 2010–2017 14
Figure 5: Diabetic Nephropathy Therapeutics Market, The US, Revenue ($m), 2005–2010 15
Figure 6: Diabetic Nephropathy Therapeutics Market, The US, Forecast ($m), 2010–2017 16
Figure 7: Diabetic Nephropathy Therapeutics Market, France, Revenue ($m), 2005–2010 17
Figure 8: Diabetic Nephropathy Therapeutics Market, France, Forecast ($m), 2010–2017 18
Figure 9: Diabetic Nephropathy Therapeutics Market, Germany, Revenue ($m), 2005–2010 19
Figure 10: Diabetic Nephropathy Therapeutics Market, Germany, Forecast ($m), 2010–2017 20
Figure 11: Diabetic Nephropathy Therapeutics Market, Italy, Revenue ($m), 2005–2010 21
Figure 12: Diabetic Nephropathy Therapeutics Market, Italy, Forecast ($m), 2010–2017 22
Figure 13: Diabetic Nephropathy Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Figure 14: Diabetic Nephropathy Therapeutics Market, Spain, Forecast ($m), 2010–2017 24
Figure 15: Diabetic Nephropathy Therapeutics Market, The UK, Revenue ($m), 2005–2010 25
Figure 16: Diabetic Nephropathy Therapeutics Market, The UK, Forecast ($m), 2010–2017 26
Figure 17: Diabetic Nephropathy Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Figure 18: Diabetic Nephropathy Therapeutics Market, Japan, Forecast ($m), 2010–2017 28
Figure 19: Opportunity and Unmet Need in the Diabetic Nephropathy Therapeutics Market 30
Figure 20: Diabetic Nephropathy Therapeutics – Strategic Competitor Assessment, 2010 32
Figure 21: Diabetic Nephropathy Therapeutics – Pipeline by Phase of Development, 2010 36
Figure 22: Diabetic Nephropathy Therapeutics – Technology Trends Analytics Framework, 2010 38
Figure 23:  Diabetic Nephropathy Therapeutics – Technology Trends Analytics Framework – Description, 2010 39
Figure 24: Diabetic Nephropathy Therapeutics – Pipeline by Mechanism of Action, 2010 40
Figure 25: Diabetic Nephropathy Therapeutics – Clinical Trials by Country, 2010 45
Figure 26: Diabetic Nephropathy Therapeutics - Clinical Trials by Phase, 2010 46
Figure 27: Diabetic Nephropathy Therapeutics - Clinical Trials by Status, 2010 47
Figure 28: Diabetic Nephropathy Therapeutics - Overall Sponsors, 2010 48
Figure 29: Diabetic Nephropathy Therapeutics - Prominent Sponsors, 2010 49
Figure 30:  Diabetic Nephropathy Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2010 50
Figure 31: Diabetic Nephropathy Therapeutics Market, Drivers and Barriers 2010 51
Figure 32: Implications for Future Market Competition in the Diabetic Nephropathy Market, 2010 52
Figure 33: Diabetic Nephropathy  Therapeutics Market – Pipeline by Company, 2010 53
Figure 34: GlobalData Market Forecasting Model 75